Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SG001 in PD-L1-positive recurrent or metastatic cervical cancer
CTR20211018Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308 in Cervical Cancer (CC), sponsored by Shangjian Bio. Started Jul 2021; status: active.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20211018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211018.